Skip to content
Ahmad Tarhini· @ATarhiniMDPhD · XThe author·· 2026-04-18Score60
Body

#AACR26 #SanDiego
@AACR
| April 20: Data supports single agent anti-tumor activity with continuous pathway inhibition in #RAS/#MAPK mutant #solidtumors & emerging best-in-class in #NRAS- & #BRAF Class II/III-mutant #melanoma | ⁦⁦
@MoffittNews
⁩

https://
aacrjournals.org/cancerres/arti
cle/86/8_Supplement/CT129/783305/Abstract-CT129-Preliminary-results-from-a-Phase-1a?searchresult=1
…

Heat 10 · 7 likes · 0 replies · 3 reposts

Conference abstracts
CT129matched by 摘要号 CT129
Preliminary results from a Phase 1a/b dose-escalation and expansion trial of the pan-RAF-MEK molecular glue NST-628 in patients (pts) with advanced or refractory RAF, KRAS, and NRAS-mutant solid tumors

Ahmad A. Tarhini, Monica Chen, Jia Liu, Varun Monga, Victoria Atkinson, Sarina A. Piha-Paul, Bartosz Chmielowski, Benjamin Herzberg, Charlotte Lemech, Prachi Bhave, Ganessan Kichenadasse, Gerald Falchook, Janice Mehnert, Andrae Vandross, Mohamad Salkeni, Meredith McKean, David Wages, Ann Marie Kennedy, Meagan B. Ryan, John Clark, Abdulaziz Nanah, Michael J. Fossler, Philip Komarnitsky, Igor Puzanov

Read the abstract →

Source: Ahmad Tarhini · x.com

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org